OTCM
APNHF
Market cap4.18bUSD
, Last price
Name
Aspen Pharmacare Holdings Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Aspen Pharmacare Holdings Limited is a global pharmaceutical entity that develops, manufactures, and distributes a wide array of specialized and branded medicinal products. The company operates through two primary segments: Commercial Pharmaceuticals and Manufacturing. Its diverse product portfolio encompasses essential anesthetic agents, such as general anesthetics, muscle relaxants, and topical preparations. Aspen also provides a comprehensive suite of thrombosis treatments, including various injectable anticoagulants like low molecular weight heparins, Xa inhibitors, and other heparin derivatives. Beyond these, the firm markets numerous regional consumer, prescription, and over-the-counter brands, such as Circadin for sleep, Foxair for respiratory ailments, Maltofer as an iron supplement, Mybulen for pain management, and Zyloric for gout. Additionally, Aspen produces active pharmaceutical ingredients and finished dose form products for other companies. Established in 1850, the company's headquarters are located in Durban, South Africa.
Related entities
Subsidiaries (14)
Aspen Finance (PTY) Limited
Aspen Global Incorporated
Aspen Healthcare FZ-LLC
Aspen Mexico S De RL De CV
Aspen Oss B.V.
Aspen Pharma Ireland Limited
Aspen Pharma Schweiz GmbH
Aspen Pharmacare Canada Inc.
Aspen Pharmacare UK Limited
Aspen Polska spolka z ograniczona odpowiedzialnoscia
ASPEN TREASURY IRELAND LIMITED
Aspen Treasury SA (Pty) Ltd
Pharmacare
Aspen Europe GMBH
Key people
Independent Non-Executive Chairman of the Board · since 2017
Stephen Saad
Group Chief Executive, Executive Director · since 2014
Chris Botha
Group Executive - Finance Manufacturing and Commercial Pharma · since 2024
Samer Kassem
Chief Executive Officer - Aspen Global Incorporated · since 2008
Pauline Macdonald
Group Executive - Supply Chain · since 2024
Trevor Ziman
Regional Chief Executive Officer - Asia Pacific · since 2001
Lorraine Hill
Group Chief Operations Officer · since 2023
Sean Capazorio
Group Finance Officer, Executive Director · since 2022
Reginald Haman
Executive Director, Group Chief Corporate Officer · since 2024
Michael Attridge
Group Chief Advisor · since 2022
Stavros Nicolaou
Group Senior Executive - Strategic Trade · since 1999
Carnie van der Linde
Senior Group Executive - Commercial (International Regions) · since 2022
Raeesa Khan
Group Company Secretary · since 2024
Ben Kruger
Lead Independent Non-Executive Director · since 2019
Christopher Mortimer
Non-Executive Director · since 1999
Non-Executive Director · since 2015
Independent Non-Executive Director · since 2018
Non-Executive Independent Director · since 2024
Themba Mkhwanazi
Independent Non-Executive Director · since 2019
Independent Non-Executive Director · since 2021
Headquarters & legal address
Building 8
Healthcare Park
Woodlands Drive
Johannesburg, GP 2052
ZA
Healthcare Park
Woodlands Drive
Johannesburg, GP 2052
ZA
Valuation
Title ZAR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑06 | 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||